{
    "address": "Vallongatan 1",
    "city": "Uppsala",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W5938H103",
    "description": "Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Uppsala, Uppsala and currently employs 30 full-time employees. The company went IPO on 2005-01-01. Product development is based on Oasmia\u2019s drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that usually require chemical solubilizers for dissolution. The firm's approved product that is using this technology is Apealea (paclitaxel micellar). Apealea has market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The firm is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region.",
    "employeeTotal": "30.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2005-01-01",
    "isin": "SE0000722365",
    "logo": "https://finnhub.io/api/logo?symbol=OASM.ST",
    "marketCapitalization": 1366.182,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Oasmia Pharmaceutical AB",
    "phone": "4618505440.0",
    "sedol": "7373534",
    "shareOutstanding": 448.37,
    "state": "UPPSALA",
    "ticker": "OASM.ST",
    "weburl": "https://www.oasmia.com/"
}